Small bowel perforation secondary to metastatic lung cancer with emphasis on the administration of erlotinib: a case report

Zhang Zhongheng; Chen Huijun; Li Xuemin

Your Location：

Home >

Browse articles >

Small bowel perforation secondary to metastatic lung cancer with emphasis on the administration of erlotinib: a case report

Updated：2026-03-12

- Small bowel perforation secondary to metastatic lung cancer with emphasis on the administration of erlotinib: a case report
- Small bowel perforation secondary to metastatic lung cancer with emphasis on the administration of erlotinib: a case report
- 解放军医学杂志（英文版） 2012年27卷第4期页码：244-248
- Affiliations：
  
  1. Department of Critical Care Medicine, Jinhua Municipal Central Hospital
  2. Department of Respiratory Medicine, Jinhua Municipal Central Hospital
  3. Department of Hepatobiliary Surgery, Jinhua Municipal Central Hospital
- Author bio：
- Funds：
- DOI：
  中图分类号： R734.2
- 纸质出版：2012
- Accepted：
Scan QR Code
Small bowel perforation secondary to metastatic lung cancer with emphasis on the administration of erlotinib: a case report[J]. 解放军医学杂志（英文版）, 2012,27(4):244-248.

[1]Zhang Zhongheng,Chen Huijun,Li Xuemin.Small bowel perforation secondary to metastatic lung cancer with emphasis on the administration of erlotinib: a case report[J].Journal of Medical Colleges of PLA,2012,27(04):244-248.
Small bowel perforation secondary to metastatic lung cancer with emphasis on the administration of erlotinib: a case report[J]. 解放军医学杂志（英文版）, 2012,27(4):244-248. DOI：

[1]Zhang Zhongheng,Chen Huijun,Li Xuemin.Small bowel perforation secondary to metastatic lung cancer with emphasis on the administration of erlotinib: a case report[J].Journal of Medical Colleges of PLA,2012,27(04):244-248. DOI：

摘要

Abstract

Small bowel metastasis from primary lung cancer is rare. Once occurs

the metastasis may cause life-threatening complications

such as bowel perforation

obstruction and bleeding. We reported an 83-year old man who presented with small bowel perforation secondary to metastatic lung cancer after being treated with erlotinib for 2 weeks. We propose that the use of erlotinib may be associated with the small bowel perforation and precautions should be taken by clinicians in initiating erlotinib for primary lung cancer when there is bowel metastasis.

关键词

Keywords

references

浏览量

Downloads

CSCD

文章被引用时，请邮件提醒。

Submit

工具集

关联资源

暂无数据